Formulation Development
Candel Therapeutics & IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
Candel Therapeutics, Inc. together with IDEA Pharma, a Division of SAI MedPartners (IDEA) recently announced a strategic commercial partnership. Under this agreement, IDEA will provide…
Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study in Metastatic Breast Cancer
BriaCell Therapeutics Corp. recently announced the external Data Safety Monitoring Board (DSMB), an independent group of experts who review and monitor the safety data of…
Dyadic Announces Funding Award to Use C1 to Accelerate Development of Protein-Based Vaccines
Dyadic International, Inc. recently announced it has received a funding award from CEPI to use C1 to accelerate the development of protein-based vaccines. CEPI is…
Longeveron Announces Positive Type B Meeting With FDA Regarding Pathway to BLA for Laromestrocel in Alzheimer’s Disease
Longeveron Inc. recently announced the positive outcome of a Type B meeting with the US FDA, supporting the advancement of laromestrocel (Lomecel-B), a proprietary, scalable,…
Acumen Pharmaceuticals Announces Topline Results From Phase 1 Study of Subcutaneous Formulation of Sabirnetug
Acumen Pharmaceuticals, Inc. recently announced topline results from its Phase 1 study comparing pharmacokinetics (PK) between subcutaneous (SC) and intravenous (IV) formulations of sabirnetug in healthy…
Conduit Pharmaceuticals Provides R&D Update on Progress for Pipeline Assets
Conduit Pharmaceuticals Inc. recently provided an R&D update on the development progress of pipeline assets AZD1656, AZD5658, and AZD5904. The Company has made significant progress…
Tract Bio Announces Publication in Gastroenterology Potential Targets for Esophageal Adenocarcinoma Identified Using stemECHOTM Cloning Platform
Tract Bio recently announced the publication of preclinical research in Gastroenterology. The article, “Evolution of Esophageal Adenocarcinoma from Precursor Lesion Stem Cells” describes results from…
Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine
Curevo Vaccine recently announced the closing of a $110-million Series B round to advance development of amezosvatein, its vaccine for shingles. Leading the round is…
llarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients
Allarity Therapeutics, Inc. announced the presentation of new clinical data from its ongoing Phase 2 trial with stenoparib monotherapy in advanced Ovarian Cancer at the…
Curia Announces Expansions to Global Network of Sterile Fill-Finish Sites
Curia Global, Inc. recently announced expansion plans to its Glasgow, UK, facility and provided updates on the ongoing expansion in Albuquerque, NM. Curia’s sterile fill-finish…
GRIN Therapeutics Receives FDA Orphan Drug Designation for Treatment of GRIN-Related Neurodevelopmental Disorder Treatment
GRIN Therapeutics, Inc. recently announced the US FDA granted Orphan Drug designation for its investigational drug, radiprodil, for the treatment of GRIN-related neurodevelopmental disorder (NDD).…
Cellphire Therapeutics CLPH-511 Fast Track Designation Granted
Cellphire Therapeutics, Inc. recntly announced the US FDA has granted Fast Track designation for CLPH-511 (Frozen Activated Platelets) Injectable Suspension for the treatment of acute…
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
Eton Pharmaceuticals, Inc recently announced positive results from its bioequivalence study of ET-600, a proprietary, patented oral solution of desmopressin under development for the treatment…
Gradalis Announces Development of Clinically Relevant Exome Sequencing Bioinformatics Pipeline to Determine Clonal Tumor Mutation Burden
Gradalis, Inc. recently announced a peer-reviewed publication in Scientific Reports. The paper details the methods and validation of Gradalis’ exome sequencing procedure and associated bioinformatics…
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
Palisade Bio, Inc. recently provided an update on its ongoing Phase 1a/b study of PALI-2108 for the treatment of Ulcerative Colitis (UC). The Company has…
Polyrizon Signs Non–Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
Polyrizon Ltd. recently announced it has signed a non-binding Letter of Intent (LOI) with a biotech company focused on psychedelic-derived therapeutics (“the psychedelic company”), to…
Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples
BEMainz Biomed N.V. recently announcedit has entered into a License and Option Agreement (the “Agreement”) with Liquid Biosciences (“Liquid”) to access a portfolio of novel…
Gattefossé Achieves Key Milestone With New US Plant Certifications
Gattefossé, a leading provider of specialty ingredients and formulation solutions for personal care and pharmaceutical industries, proudly announces the successful certification of its new manufacturing…
Kaerus Bioscience Successfully Completes Phase 1 Trial & Demonstrates Proof of Mechanism With its Novel BK Channel Modulator KER-0193 Being Developed for Fragile X Syndrome
Kaerus Bioscience recently announces the successful completion of its Phase 1 clinical trial of KER-0193, a novel BK channel modulator the company is developing for Fragile…
Exogenus Therapeutics Chooses Lonza to Develop a GMP-Compliant Process to Manufacture Exo-101, its Lead Exosome-Based Candidate
Exogenus Therapeutics, a Portuguese biotech company, and Lonza, a global development and manufacturing partner to the pharmaceutical and biotech markets, announced today a collaboration to…
